drugset / Trial / NCT04959786

MANS-NRIZ Trial for COVID-19 Treatment : Extension Study

NCT04959786

Phase 2/3 Unknown 100 enrolled Mansoura University
RandomizedParallel-groupSingle-blindTreatment

Summary

This search will focus on patients with COVID 19 infection this study is a prospective cohort study based on the analysis of response in comparative panel between two arm Nitazoxanide, Ribavirin and Ivermectin plus Zinc arm and other arm without any intervention as regards the safety and efficacy and cost effective result. Two years duration of the project would be enough to cover the stages of the work as shown below in the time plan. Initial stage of collecting materials and patients' clinical data, each patient will undergoes strict follow up period to reveal the clinical, laboratory and radiological response. The procedures are to be approved by the institutional ethical committee.

Timeline

Start
2021-04-01
Primary completion
2022-11
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivermectin Small molecule Oral
Subject Nitazoxanide Other / unclassified Oral
Subject Ribavirin Small molecule Oral
Subject Zinc Sulfate Unknown Oral

Indications